The project proposal is in line with the wording of the call for applications for a non-repayable financial contribution to support the mobilisation and exploitation of the potential of research institutions in fighting the COVID-19 pandemic and reducing the negative consequences of the pandemic. It focuses on the development of substances with a multi-modal effect for the development of therapeutics and nutritional supplements applicable to viral pandemics, currently in the COVID-19 pandemic. Multi-modal effect means that in addition to the key antiviral effect, antibacterial, anti-inflammatory, immunostimulating or antioxidant effects are expected, which can speed up treatment and prevent complications. The creation of the project was positively influenced by the existence of the cluster “Omics4Health”, which brings together important scientific centres of SAS, universities and universities and companies active in the field of farm research and applications. The cluster developed a comprehensive, consistent and original project idea with multi-member involvement. At the same time, the project proposal builds on existing projects that address partial development of original substances with antibacterial effect or anti-inflammatory and antioxidant effect. It makes appropriate use of the manufacturing research potential of the production of beta-glucans with an immunostimulating effect in NPPC. Among the interests of the applicant for a grant application to Sitno Pharma, s.r.o., is the production of innovative parenteral forms of therapists. At present, their application against COVID-19 appears to be desirable and highly topical. The project proposal exploits the available scientific potential for the development of new medicinal entities, solves practical matters related to the application and finalisation of the intended products, in particular the impact of process operations on the preservation of the above properties. The project proposal consists of five activities. Activities 1 and 2 (CHÚ SAS Bratislava), similarly Action 3 (NPPC Lužianky), are aimed at generating new entities with appropriate analytical support, Activity 4 (CEM SAV Bratislava) is aimed at evaluating individual activities within the defined multi-modal effect. Activity 5 (Sitno Pharma, s.r.o.) addresses the necessary steps to complete the production park and key studies to verify the impact of process operations on the maintenance of the defined therapeutic activities of the products being developed. The design of the project is based on the optimal structure of the required funds for the completion of the production park, the purchase of key equipment, personnel costs, the purchase of chemicals, bio-reagents and consumables. The project is built to provide high-quality scientific outputs in the course of the solution, as well as defined forms within the framework of the protection of intellectual property achievements in the international field. During the solution, the project will create new jobs and after the end of the solution phase it will provide the prerequisites for the continuation and financial autonomy of the proposed plan.